Coronary disease risk curve of serum creatinine is linear in turkish men, U-shaped in women

Journal of Investigative Medicine

Volumn 61, Issue 1, 2013, Pages 27-33

  Onat, Altan ^a,b,f   Can, Günay ^b   Ademoǧlu, Evin ^c   Çelik, Etem ^d   Karagöz, Ahmet ^e   Örnek, Ender ^d  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d Etlik Ihtisas Education Hospital   (Turkey)

^e ANKARA NUMUNE HOSPITAL   (Turkey)

^f Nisbetiye Cad 59/24   (Turkey)

Author keywords

Apolipoprotein A I; Coronary heart disease risk; Proinflammatory state; Serum creatinine; Sex difference

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; REVIEW;

BIOLOGICAL MARKERS; CORONARY DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS; TURKEY;

EID: 84873620459     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318276de59     Document Type: Review

References (30)

1. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034-2047.
2. Garg AX, Clark WF, Haynes RB, et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61:1486-1494.
3. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55.
4. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
5. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
6. Van Biesen W, De Bacquer D, Verbeke F, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007;28:478-483.
7. Di Angelantonio E, Danesh J, Eiriksdottir J, et al. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med. 2007;4:e270.
8. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
9. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
10. Wannamethee SG, Shaper AG, Lowe GDO, et al. Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers. Eur Heart J. 2006;27:2975-2981.
11. Onat A, Ceyhan K, Başar ö, et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels Va prospective and cross-sectional evaluation. Atherosclerosis. 2002;165:285-292.
12. Onat A, Hergenç G, Bulur S, et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol. 2010;142:72-79.
13. Onat A, Can G, Ayhan E, et al. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism. 2009;58:1393-1399.
14. Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism. 2011;60:499-512.
15. Rye K-R, Barter P. Function and metabolism of pre-beta migrating, lipid-poor apolipoprotein A-I. Artrioscler Thromb Vasc Biol. 2004;24:421-428.
16. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis. 2001;156:1-10.
17. Onat A, Hergenç G, Uyarel H, et al. Association between mild renal dysfunction and insulin resistance or metabolic syndrome in a random nondiabetic population sample. Kidney BP Res. 2007;30:88-96.
18. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
19. Onat A, Uyarel H, Hergenç G, et al. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis. 2007;191:182-190.
20. Rose GA, Blackburn H, Gillum RF, et al. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: World Health Organization; 1982:124-127.
21. Praught ML, Shlipak MG. Are small changes in serum creatinine an important risk factor? Curr Opin Nephrol Hypertens. 2005;14:265-270.
22. Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol. 2004;15:1897-1903.
23. Nordestgaard BG, Chapman MJ, Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
24. Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 1997;8:1889-1898.
25. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105-115.
26. 2 yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med. 2011;49:1349-1357.
27. Onat A, Hergenç G, Ayhan E, et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor among Turks. Diabet Med. 2009;26:981-988.
28. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
29. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55:1932-1943.
30. Rule AD, Rodeheffer RJ, Larson TS, et al. Limitation of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc. 2006;81:1427-1434.